广济药业索赔时效告急，已有案件审理中

Core Viewpoint - The article discusses the legal proceedings against Guangji Pharmaceutical due to financial reporting irregularities, highlighting the potential for investor compensation through a class action lawsuit [1][2][3]. Group 1: Legal Proceedings - A new batch of cases has been submitted to the court by the Liu Peng lawyer team from Shanghai Huzhi Law Firm, currently seeking affected investors [1][2]. - The case was initiated after Guangji Pharmaceutical received an administrative penalty decision from the Hubei regulatory authority on July 22, indicating issues with the company's financial reports [1][2]. Group 2: Financial Reporting Irregularities - Guangji Pharmaceutical's subsidiary, Hubei Guangji Pharmaceutical Jikang, reported inflated revenues by using the gross method instead of the net method for revenue recognition, leading to overstatements of 45.60 million yuan, 136.86 million yuan, and 138.20 million yuan for the first, half, and third quarters of 2022, respectively, which accounted for 25.49%, 26.68%, and 20.49% of the reported revenues for those periods [3]. - The company issued a correction announcement in April 2023, acknowledging the accounting errors for the first three quarters of 2022, which were deemed violations of the Securities Law of the People's Republic of China [2][3].